A Randomized, Single-dose, Open-label, Single-center, Crossover Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
Latest Information Update: 04 Nov 2022
At a glance
- Drugs Mitiperstat (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 31 Oct 2022 Status changed from recruiting to completed.
- 30 Aug 2022 Status changed from not yet recruiting to recruiting.
- 18 Jul 2022 New trial record